European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

On Monday, 74-year-old Ralph Carmona of Portland will be the only qualified Boston Marathon runner with Alzheimer's.

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...

Last accessed: April 2025. Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: April 2025. The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now ...